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groups, and none of the events were assessed as possibly 
intervention-related by the investigators.
Conclusions This trial confirmed the effective and safe use 
of dietary management with l-arginine in combination with 
B vitamins. The primary efficacy analysis demonstrated a 
statistically significant superiority of the combination of 
l-arginine with B vitamins over placebo in improving and 
restoring impaired endothelial function and lowering BP in 
patients with mild to moderate blood pressure elevation.
Keywords Endothelial function · Atherosclerosis · Blood 
pressure · l-Arginine · B vitamins
Introduction
Mediated by nitric oxide (NO), intact endothelial cells 
control vascular homoeostasis by regulating vascular tone 
and preventing smooth muscle cell proliferation, mono-
cyte adhesion to the endothelium and platelet aggregation, 
thereby protecting blood vessels from the formation of 
atherosclerosis [1]. Endothelial dysfunction (ED) is char-
acterized by a reduced bioavailability of NO as well as 
an impairment of endothelium-dependent vasodilatation 
[2–4]. NO is formed from the semi-essential amino acid 
l-arginine by the endothelial nitric oxide synthase (eNOS) 
enzyme as long as the B vitamins B6, folic acid and B12 
are provided at sufficient levels [5]. NO is involved in 
numerous regulatory mechanisms of the vascular system, 
and lack of NO is now widely regarded as a key molecular 
mechanism causing cardiovascular disease [4, 6–8]. Ather-
osclerotic cardiovascular diseases are the leading cause of 
morbidity and mortality [9].
Atherosclerosis is initiated by the response of vascular 
endothelial cells to injury caused by cardiovascular risk 
Abstract 
Purpose The aim of this trial was to investigate the influ-
ence of a dietetic product consisting of a unique combina-
tion of l-arginine with the vitamins B6, folic acid and B12 
(Telcor® Arginin plus) on endothelial dysfunction.
Methods Subjects aged 40–65 years with mild to moderate 
blood pressure (BP) elevation not treated with anti-hyper-
tensive drugs were randomly assigned to either the die-
tetic product (n = 40) or a matching placebo (n = 41) for 
3 months with open follow-up for a further 3 months. Post-
prandial change in endothelial function was assessed using 
the validated reactive hyperaemia index (RHI) at 3 months 
compared to the study onset (RHI post–pre, visit 3–visit 1; 
ΔΔRHI). Secondary parameters included BP and plasma 
homocysteine concentration.
Results The primary efficacy analysis revealed superiority 
of the nutritional intervention over placebo (p = 0.0349) in 
reducing the deterioration of endothelial function. While 
in the active group ΔΔRHI increased (0.371 ± 0.122), 
almost no change could be detected in the placebo group 
(0.031 ± 0.100), thus demonstrating a significant improve-
ment in vascular function in the intervention group. Moreo-
ver, the intervention reduced BP and homocysteine levels. 
Non-serious adverse events were equally distributed in both 
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factors such as essential hypertension, several forms of 
dyslipidemia, diabetes mellitus, cigarette smoking, age-
ing, hyperhomocysteinemia, obesity and lack of physical 
activity [4]. Continuous exposure to various risk factors 
promotes plaque progression and destabilization which 
ultimately results in plaque rupture and an acute thrombotic 
occlusion of one or more coronary or brain arteries, caus-
ing stroke or myocardial infarction. The vascular endothe-
lium serves as a barrier separating the vessel wall from the 
blood and as such constitutes a primary sensitive target for 
the damaging effects of atherogenic risk factors.
NO is a potent endogenous vasodilator and inhib-
its aggregation of platelets, adhesion of monocytes to the 
endothelium and smooth muscle cell proliferation [1–3, 
5, 10]. Together, these functions make NO a significant 
endogenous anti-atherosclerotic mediator.
One mechanism that explains the occurrence of ED and 
the lack of NO is the presence of elevated blood levels of 
asymmetric dimethylarginine (ADMA), an l-arginine ana-
logue, in patients with cardiovascular diseases [3, 11–15]. 
ADMA is an endogenous inhibitor of the NO synthase that 
inhibits NO formation, and in this way it can also impair 
vascular function. ADMA displaces l-arginine from its 
binding sites that enable NO formation, binding to them 
with a tenfold higher affinity [11, 16, 17].
Cardiovascular diseases are associated with low l-argi-
nine levels and a high ADMA: l-arginine ratio that reduces 
the bioavailability of NO [15, 18]. This imbalance is not 
only facilitated further by the inadequate synthesis and 
increased degradation of NO, but also by an increased loss 
of the substrate l-arginine. The availability of l-arginine 
can further be affected by the fact that 50–70% of dietary 
l-arginine is metabolized by the intestinal mucosa and does 
not even enter the circulation [19]. Studies have shown that 
dietary supplementation with l-arginine efficiently reverses 
the ED in patients with high ADMA levels and augments 
NO production [17]. In addition, l-arginine supplementa-
tion results in enhanced inhibition of platelet aggregation 
and monocyte adhesion and reduces vascular smooth mus-
cle cell proliferation [20].
With advanced age, the physiological demand for l-argi-
nine increases considerably [11, 12, 17]. Ageing is often 
associated with cardiovascular disease since ADMA levels 
are increased fourfold during advanced age [17].
Although some studies showed mixed results as regards 
the effects of an l-arginine supplementation on cardio-
vascular parameters (which may have been due to patient 
selection, dosing regimens and individual variation [21]), 
the majority of more recent studies show that supple-
mentation with l-arginine restores vascular function and 
improves the clinical symptoms of various diseases associ-
ated with vascular dysfunction [22–27]. A widely criticized 
study was published by Schulman and colleagues in 2006 
[28], allegedly showing a higher rate of fatalities in subjects 
with acute ST-segment elevation myocardial infarction and 
who had received 9 g l-arginine per day. The study, which 
was not powered for mortality, was stopped early and con-
sidered unreliable in the following years due to relevant 
study limitations [29, 30]. So, in a review by Shao and 
Hathcock and a letter to the editor by Abumrad and Bar-
bul, the authors state that the outcome is inconsistent with 
the body of literature and appears to be a random anomaly 
[29, 30]. In numerous clinical studies, the administration of 
l-arginine showed promising effects in patients with car-
diovascular and other diseases, and such effects have been 
confirmed by meta-analyses and recent systematic reviews 
[5, 22–25, 31–33].
Further studies have shown that a normalization of 
blood flow and blood pressure (BP) as well as a reduction 
in homocysteine levels can be achieved by dietary adminis-
tration of l-arginine and sufficient amounts of B vitamins 
[4, 5, 17, 22, 23, 34, 35], even at low doses of 3 g per day 
[16, 22, 23]. l-arginine and B vitamins are particularly 
apt at restoring endothelial health and reversing vascular 
degeneration and do this by stimulating nitric oxide forma-
tion [5, 17]. In the study presented here, our intention was 
to confirm this using a special dietary combination which 
was characterized by low amounts of l-arginine, vitamin 
B6, folic acid and vitamin B12. An editorial published in 
Cardiovascular Research on l-arginine and B vitamin sup-
plementation in 2012 further encouraged this investigation 
reporting on their potent synergistic vasoprotective effects 
[36]. The study was a controlled trial investigating the effi-
cacy, safety and tolerability of a specific combination of 
l-arginine and B vitamins (intervention) and particularly 
its influence on ED and associated diseases such as hyper-
tension and hyperhomocysteinemia in subjects with mild 
to moderately elevated BP. Since the induction of ED by 
provision of a fatty meal [37] can be considered as a recog-
nized method for clinical trials, and since reactive hyperae-
mia peripheral arterial tonometry (RHI) adequately depicts 
the overall health of the endothelium [38, 39], both meth-
ods were chosen to evaluate the endothelial function before 
and after dietary intervention.
Methods
The controlled interventional trial was performed as a con-
firmatory, prospective, randomized, placebo-controlled, 
double-blind, single-centre study.
Intervention products Telcor® Arginin plus (TAP); 2 
capsules b.i.d.; total daily amounts: 2.4 g l-arginine, 3 mg 
vitamin B6, 0.4 mg folic acid, 2 µg vitamin B12 (interven-
tion) or a matching placebo with the same visual appear-
ance containing of microcrystalline cellulose.
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Subjects 81 eligible subjects aged 40–65 years (age 
53.8 ± 5.8 years, BMI 25.3 ± 2.7 kg/m2, 37% female, all 
non-smokers) were randomly assigned to receive either the 
nutritional intervention (n = 40) or a matching placebo 
(n = 41) for 3 months. During the subsequent follow-up 
phase, all subjects received TAP intervention for 3 months.
Subjects had to be either male or female (postmenopau-
sal) aged 40–65 years with slightly to moderately elevated 
BP (130 to ≤149 mmHg SBP) and had to be under assess-
ment for other risk factors (end organ damage, diabetes, 
clinically relevant cardiovascular diseases) and not receiv-
ing and not requiring any antihypertensive drug therapy 
(defined by the German hypertension guideline/Deutsche 
Hochdruckliga). Moreover, subjects characterized by 
severe cardiovascular diseases, obesity (BMI >30 kg/m2), 
interfering medication (e.g. anti-hypertensives, PDE-5 
inhibitors) or sleep apnoea were excluded. They also had 
to be non-smokers. Participants were asked to maintain 
their usual diet, medications and lifestyle during the entire 
course of the study. Alcohol consumption and physical 
activity 24 h before the measurements were prohibited. 
Lifestyle changes were evaluated by using questionnaires 
at visits 3 and 5.
Overall trial design This controlled interventional trial 
was performed as a monocentric, randomized, placebo-
controlled, double-blind, parallel group trial for the first 
3 months in phase I which was then followed by an open 
3-month follow-up phase during which the intervention 
was given to all participants in phase II (Fig. 1). Randomi-
zation was made using a computer-generated randomiza-
tion list. Moreover, randomization was stratified by gender. 
The compliance as assessed by counting capsules usage 
exceeded 95% in both study phases. Trial registration: Ger-
man Clinical Trials Register No.: DRKS00010276.
Trial Endpoints The primary endpoint was defined as the 
postprandial (fatty meal, FM-induced) change in endothe-
lial function assessed by means of the validated reactive 
hyperaemia index (RHI) at 3 months compared with the 
study onset (RHI post–pre, visit 3–visit 1; the ΔΔRHI). 
The primary efficacy analysis focused on the difference 
between intervention and placebo for assessing the pos-
sible impact of l-arginine and B vitamins in preventing 
FM-induced ED. Secondary efficacy parameters included 
changes in BP and homocysteine levels. All parameters 
were monitored over the entire study period of 6 months. 
Compliance, safety and tolerability of the intervention 
were determined by questionnaires, physical examinations, 
electrocardiography and routine clinical and laboratory 
parameters.
Assessment of endothelial function Normal physiologi-
cal functioning of the endothelium was assessed by reac-
tive hyperaemia peripheral arterial tonometry using the 
non-invasive EndoPAT™ (Itamar Medical Inc., Franklin, 
MA, USA) procedure [40]. The EndoPAT system is based 
on peripheral arterial tone (PAT) signal technology, a non-
invasive plethysmographic method measuring pulsatile 
volume changes in the digital bed. The user-independent 
test was performed in a temperature-controlled and quiet 
environment. The test quantifies endothelium-mediated 
changes in vascular tone elicited by a 5-min occlusion of 
the brachial artery using a standard BP cuff inflated to a 
suprasystolic pressure. When the cuff was deflated, the 
surge of blood flow caused an endothelium-dependent, 
flow-mediated dilatation leading to reactive hyperaemia 
Fig. 1  Trial design
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and an increase in the PAT signal amplitude. Measurements 
from the contralateral probe were used to control for non-
endothelial-dependent changes in vascular tone. The pos-
tocclusion-to-preocclusion ratio, called the EndoScore or 
the reactive hyperaemia index (RHI), was calculated using 
the EndoPAT™ 2000 software [41]. A normal RHI score 
is defined as 1.67 or higher while lower values indicate 
vascular dysfunction which is related to an impairment of 
endothelium-dependent vasodilatation, and which is con-
sidered to be an independent predictor of cardiovascular 
morbidity and mortality [42, 43].
Impairment of endothelial function was induced by a 
fatty meal consisting of 30% cream at 3 ml/kg. Baseline 
measurements were conducted in the morning after a stand-
ardized meal in the evening before. TAP was administered 
at least 8–12 h before baseline and 30 min before intake of 
fatty meal at visits V3 and V5.
Homocysteine Plasma homocysteine levels were deter-
mined using an S-Monovette® with 2.7 ml HCY/Z-Gel 
(Sarstedt, Nümbrecht, Germany) and HPLC.
Blood Pressure: Home BP monitoring: 7 days before 
each visit, the volunteers performed daily BP measure-
ments at home using a standardized device (Boso® medicus 
PC 2). Data were collected each day in the morning. Every 
measurement was documented along with the time and 
date. The mean of these 7 days for systolic and diastolic 
BP was used for evaluating the BP. Ambulatory blood pres-
sure monitoring (ABPM): BP readings were performed on 
the day of visit on an ambulatory basis over 24 h by using 
a standardized monitoring device (Boso® TM-2430 PC 2) 
which collected data (systolic pressure, diastolic pressure, 
heart rate and mean arterial pressure) every 15 min during 
the day and every 30 min during the night.
Statistics Appropriate statistical analyses were per-
formed using GraphPad Prism version 5.0 (GraphPad 
Software Inc., La Jolla, CA, USA). All parameters were 
analysed on an intention-to-treat (ITT) basis by descriptive 
and inferential statistics. Based on available empirical evi-
dence [44, 45], the calculated sample size was 37 for each 
group (alpha 0.05, power 0.80). Data distributions were 
checked for normality using the Shapiro–Wilk test. The 
primary endpoint was analysed in a confirmatory manner 
by applying an unpaired t test and comparing the change 
of the reactive hyperaemia index (RHI) at 3 months and 
at the study onset between the two groups. For changes 
within groups, the paired t test was employed. If data were 
not normally distributed, Wilcoxon matched pairs signed 
rank test was used. For evaluation of 7-day BP changes 
within a group, the data were analysed by using a repeated 
measures ANOVA test. If data were not normally distrib-
uted, the Friedman test was applied. Differences between 
parallel groups were evaluated by using an unpaired t 
test. If the differences were not normally distributed, the 
Mann–Whitney U test was applied. All statistical tests 
were performed as two-sided. Generally, a significance 
level of 0.05 was used.
Results
The presentation of the efficacy results during phase I and 
of the safety results during phases I and II are based on the 
intention-to-treat (ITT) analysis. The efficacy results from 
the open follow-up phase II are based on per-protocol (PP) 
analysis. All results of the ITT analysis were confirmed by 
the PP analysis.
Subjects From 81 enrolled subjects with slightly to mod-
erately elevated BP, a total of 80 completed the entire study 
protocol resulting in 40 subjects for each group (Fig. 2). 
The compliance regarding the intake of study products for 
both study phases was very good in both groups. At base-
line, nutritional status (0 = healthy, balanced nutrition, 
100 = unbalanced nutrition) and individual stress level 
[46] (20 items in 4 categories resulting in 0 = no stress to 
100 = maximum stress) were assessed by means of ques-
tionnaires (Table 1). 
Changes in ΔΔRHI At baseline, no differences were 
detected between the two groups (p = 0.316). After 3 
months, the primary study endpoint (changes in RHI post–
pre, visit 3–visit 1; active compared to placebo, ΔΔRHI) 
reached statistical significance with a value of p = 0.0349. 
While in the active group ΔΔRHI increased significantly, 
almost no change could be detected in the placebo group 
(Fig. 3). Before and after the fatty load ΔΔRHI was 
increased in the intervention group by 0.371 ± 0.122, while 
in the placebo group ΔΔRHI increased by 0.031 ± 0.100. 
During visits 3 and 5, the significant increase in ΔΔRHI 
(p = 0.001) was confirmed in the intervention group, while 
no significant differences were found for the placebo group 
(p = 0.758).
Blood pressure During the first 3 months of supplementa-
tion, the systolic BP decreased significantly in both groups. 
In the placebo group, the decrease stagnated between vis-
its 2 and 3 (systolic placebo V1: 138.0 ± 5.39 mmHg; V2: 
133.2 ± 9.24 mmHg; V3: 133.0 ± 10.13 mmHg), whereas 
in the intervention group systolic values decreased further, 
similar to the decrease seen between visits 1 and 2 (sys-
tolic BP V1: 138.7 ± 5.11 mmHg; V2: 136.0 ± 7.94; V3: 
133.8 ± 6.99 mmHg). The continuous decrease in the 
active group may have indicated substance effects, which 
was supported by the further analysis of the active group 
over the next 3 months of supplementation. Between vis-
its 1 and 5, the fall in systolic BP was highly significant 
(p < 0.0001) so that values of 132.5 ± 7.22 mmHg were 
attained, although no significant inter-group differences 
were evident.
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In the active group, there was a tendential decrease in 
diastolic BP from 87.7 ± 6.59 to 85.8 ± 6.79 mmHg, 
p = 0.061). Compared to placebo, the decrease was more 
pronounced in the active group (Δ diastolic BP V2–V1 pla-
cebo: −0.1 ± 5.42; intervention: −1.9 ± 4.27; p = 0.103). 
The results were further substantiated by the PP analy-
sis: in the intervention group, diastolic values decreased 
significantly already after 3 months of supplementation 
(p = 0.048). In comparison with placebo, a trend indicat-
ing a reduction in diastolic BP was observed (p = 0.093). 
Over the ensuing 6 months of supplementation, the 
decrease in diastolic values in the intervention group then 
reached statistical significance (V1: 87.61 ± 6.775 mmHg; 
V3: 85.1 ± 6.966 mmHg; V5: 84.08 ± 7.354; p = 0.002), 
which confirms the positive influence of the dietary 
Fig. 2  Subjects
Table 1  Baseline characteristics of both groups
Values are mean ± SD
a Mann–Whitney U test, bunpaired t test
Intervention Placebo p
n 40 40
Age (years) 53.23 ± 6.41 54.30 ± 5.14 0.494a
Weight (kg) 78.45 ± 12.04 74.75 ± 12.21 0.176b
Height (m) 1.74 ± 0.10 1.73 ± 0.09 0.544b
BMI (kg/m2) 25.74 ± 0.40 24.83 ± 0.44 0.133b
Nutrition (score) 49.55 ± 8.11 48.03 ± 10.40 0.467b
Stress level (score) 34.00 ± 14.64 29.31 ± 17.29 0.194b
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intervention on BP. The subgroup analysis revealed that the 
antihypertensive effect of the intervention was particularly 
evident in men where the decrease in diastolic BP was sig-
nificant between the groups (p = 0.039).
Nocturnal BP dipping Within the first 3 months of inter-
vention, there was a tendential increase in the magnitude of 
systolic nocturnal dipping in the intervention group com-
pared to the placebo group. A similar trend was seen for 
the diastolic nocturnal dipping. This effect in the interven-
tion group during the first 3 months of supplementation 
was further reinforced during the subsequent 3 months of 
supplementation, when the nocturnal dipping of systolic 
(p = 0.012) and diastolic BP (p = 0.031) reached signifi-
cance (Fig. 4).
Homocysteine blood concentration After 3 months 
of supplementation, the homocysteine blood concentra-
tions were significantly decreased from 10.2 ± 4.2 to 
8.56 ± 2.04 µmol/l in the intervention group (p = 0.0001), 
whereas the values remained stable in the placebo 
group. The difference between the groups was statisti-
cally significant (p = 0.0004) with reductions amount-
ing to +0.05 ± 1.29 µmol/l in the placebo group and 
−1.61 ± 3.34 µmol/l in the intervention group (Fig. 5).
In the intervention group, the reduction in homocysteine 
concentration was retained over the whole trial period. In 
the placebo group, when intervention was reverted to dur-
ing the open phase, there was also a significant reduction 
by −1.41 ± 1.53 μmol/l compared to the levels measured 
after 3 months of placebo intervention.
Safety and tolerability All recorded adverse events (AE) 
were non-serious, and no difference in the frequency of AE 
could be detected between the groups. During the blinded 
parallel phase, in the placebo group, a total of 20 (48.8%) 
subjects with AE were recorded compared to 19 (47.5%) 
in the TAP group [31 (38.8%) of n = 80 during the follow-
up]. Three participants assessed the AE (gastrointestinal 
tract disturbance; short time sleeping disturbances) as pos-
sibly related to TAP; however, the investigators judged the 
causal relationship as unlikely in all cases. There were no 
clinically relevant laboratory parameter changes in either 
group. Additional metabolic or inflammation parameters 
such as serum lipids or high-sensitivity C-reactive protein 
(not shown) were not influenced during the trial period and 
strongly support therapeutic safety. In both groups, most 
of the participants rated the tolerability with the maximum 
score of good. The findings confirmed the excellent safety 
profile of the investigational product.
Discussion
This trial confirms the efficacy, safety and tolerability of 
a dietary intervention combining l-arginine and B vita-
mins for the purposes of improving cardiovascular health. 
The primary efficacy analysis demonstrates a statistically 
significant superiority of the l-arginine and B vitamin 
Fig. 3  Improvement in endothelial function brought about by l-argi-
nine and B vitamins. Values are mean ± SEM; unpaired t-test, ITT 
population
Fig. 4  Enhanced night-time BP reduction (nocturnal dipping) after 
long-term dietary intervention in the intervention group. 1rmANOVA, 
ITT population
Fig. 5  Reduction in homocysteine after 3 months. Mann–Whitney U 
test, ITT population
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combination over placebo in improving and restoring the 
impaired endothelial function after fat loading in a group of 
subjects with slightly to moderately elevated BP.
The significant improvement in endothelial function in 
the intervention group indicates that l-arginine in combi-
nation with B vitamins is able to improve vascular func-
tion even after a strong dysfunctional trigger such as a 
fatty meal challenge. This effect was fully maintained over 
the entire trial duration of 6 months which demonstrates 
a long-lasting effect of the diet on the improvement in 
endothelial function.
All three main parameters and risk factors for cardiovas-
cular disease, namely endothelial function, BP and homo-
cysteine levels, were positively influenced by the nutrients. 
The positive effects were achieved by a daily supplementa-
tion of only 2.4 g of l-arginine in combination with small 
amounts of B vitamins. The results obtained suggest that 
the nutritional combination of l-arginine and B vitamins 
can successfully be employed to control cardiovascular risk 
factors, to improve endothelial function and to develop a 
dietary intervention of the early stages of atherosclerosis, 
stages which are associated with mild hypertension and 
hyperhomocysteinemia as well as moderately to slightly 
enhanced metabolic stress as defined by enhanced superox-
ide anion radical formation.
The findings from the current trial are consistent with 
numerous recent clinical studies, systematic reviews and 
meta-analyses of relevant clinical data in this field [1, 4, 5, 
17, 22–24]. They demonstrate that a dietetic approach can 
successfully be employed to address ED at a very early 
stage of cardiovascular disease, which may therefore help 
to prevent progression and degenerative changes and lower 
the risk of severe complications.
The positive effect of l-arginine on impaired endothe-
lial function has previously been demonstrated in volun-
teers after acute administration of 2.5 g of this amino acid 
[37]. Endothelial function induced by a fatty meal was 
determined by flow-mediated dilatation 1 h postprandial. 
The amino acids l-phenylalanine and l-leucine, however, 
did not prevent lipemic ED. In addition, l-arginine given 
alone without B vitamins had no acute effect on baseline 
flow-mediated dilatation. Thus, this study confirms and 
extends these findings by demonstrating the long-term 
efficacy of l-arginine in combination with vitamin B6, 
folic acid and vitamin B12 in preserving endothelial func-
tion in a population of subjects with slightly or moderately 
elevated BP. Comparable effects of l-arginine were dem-
onstrated in numerous other clinical studies. The avail-
able findings were the subject of a systematic review with 
a meta-analysis published by Bai et al. [22] who demon-
strated the efficacy of l-arginine in restoring endothelial 
function. The authors of this meta-analysis concluded that 
the studies show a normalization of endothelial function 
only in subjects who had substantially impaired vascular 
health. Sydow and Böger also discussed this topic in detail, 
explaining why l-arginine in contrast to B vitamins given 
alone can counteract ED in hyperhomocysteinemia [47]. 
However, until now we are not aware of any studies dem-
onstrating efficacy of a low-dose combination of the car-
diovascular nutrients l-arginine, vitamin B6, folic acid and 
vitamin B12 in restoring endothelial function over a period 
of 6 months.
l-arginine is a conditionally essential amino acid in the 
human diet [1, 2], and the most common dietary sources of 
l-arginine are meat, poultry and fish. However, individuals 
with poor nutrition or under conditions of increasing age 
and certain physical conditions, e.g. ED, hypertension or 
diabetes, may be advised to supplement l-arginine in suf-
ficient amounts. In a recent study, Ganz and colleagues 
demonstrated that serum l-arginine levels are lower in indi-
viduals with type 2 diabetes mellitus compared to controls, 
and that l-arginine levels were inversely related to HgbA1c 
[18]. l-arginine, which acts by many different signal trans-
duction pathways, is the most important precursor for the 
synthesis of nitric oxide (NO), a key signalling molecule. 
Reduced bioavailability of vasoprotective NO plays an 
essential role in cardiovascular pathologies and metabolic 
diseases. NO synthases (NOS) oxidize the NO precursor 
l-arginine to NO and citrulline [1, 2].
Tetrahydrobiopterin (BH4) is a cofactor for several 
important enzyme systems including the NOS isozymes 
[5]. Experimental and clinical studies implicate BH4 as a 
key regulator of NO formation from l-arginine by eNOS. 
As such, BH4 has to be considered a key factor in deter-
mining cardiovascular health and disease [48–51]. The 
augmentation of endothelial BH4 levels by folic acid has 
been shown to enhance NO formation (for review see [5]). 
Folates are able to increase gene and enzyme expression as 
well as NO formation by acting as cofactors or recycling 
agents for BH4. They increase bioavailability and bioactiv-
ity of BH4 and prevent premature degradation with uncou-
pling of the enzyme to produce superoxide anion radicals 
instead of NO [51–53]. Whereas folic acid directly affects 
NO formation from l-arginine, the other B vitamins can 
support several additional metabolic processes that safe-
guard NO formation from its endogenous substrate [51, 
52]. The most important metabolic pathways that are tar-
geted by B vitamin supplementation have been identified 
[5, 47, 51, 52] and have been shown to be operational 
under administration of l-arginine and these micronutrients 
(Fig. 6).
In addition, the synergistic effect of B vitamins should 
improve the NO-mediated responses induced by l-arginine. 
Since superoxide anion radicals can be generated upon 
uncoupling of NO synthesis from its endogenous precursor 
l-arginine through transfer of electrons to oxygen instead, 
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the addition of antioxidative B vitamins can safeguard the 
necessary coupling reaction and therefore prevent oxidative 
or nitrosative stress associated with high homocysteine and 
ADMA levels.
In the current clinical study, it could be confirmed that 
even relatively low nutritional amounts of l-arginine, if 
combined with small amounts of vitamins B6, folic acid 
and B12, can effectively prevent ED induced by a fat load. 
Most commonly, in clinical studies endothelial function is 
measured by using flow-mediated dilatation (FMD) of the 
brachial artery [54–56]. However, FMD is known to be 
highly user dependent since it requires specially trained 
personnel [57]. In this study, we employed the non-inva-
sive, easy-to-use and user-independent pulse amplitude 
tonometry (EndoPAT) which has already extensively been 
used in several studies assessing endothelial function [57–
61]. In addition, this method adequately depicts the overall 
health of the endothelium [38, 39] which corresponds with 
the indication of the nutritional product and which empha-
sizes that the endpoint is not only validated, but also clini-
cally important.
In numerous studies, endothelial function is measured 
by brachial artery flow-mediated dilatation (FMD) 3 h 
after a fat load [37, 62, 63]. However, while FMD meas-
ures the endothelial function of the macrovascular system, 
the EndoPAT technique measures the endothelial func-
tion in the microvascular system. Since it was shown that, 
compared to the macrovascular system, the reaction of the 
microvascular system to postprandial challenge is faster 
[64], the measurement point was set to 1 h following a fat 
load. Since a comparable combined metabolic and endothe-
lial function effect is not known from the individual nutri-
ents at the given doses, synergism of their combination 
can be reasonably assumed resulting in a long-lasting and 
statistically significant vascular effect which was a major 
finding of this study. The contribution of B vitamins to 
the BP-lowering effects of l-arginine by potentiating the 
response to the amino acid is consistent with the literature 
[5, 47, 51, 52].
The restoration and maintenance of endothelial function 
enable NO-induced vasodilatation which is supported by 
a significant blood pressure reduction as demonstrated by 
a meta-analysis of clinical studies where active treatment 
was given in the form of l-arginine [23]. Vasodilatation by 
NO can lower BP by simultaneously increasing blood flow 
[1, 2].
Home blood pressure monitoring was included to over-
come bias in office-based BP readings such as digit pref-
erence, observer bias [65] or the “white coat effect”. 
Compared to office-based BP measurements, home BP 
monitoring holds superior reproducibility and, in addi-
tion, predictive ability in terms of hypertensive target organ 
damage and prognosis of cardiovascular disease [66].
In the current trial, mild to moderate hypertension was 
chosen as an inclusion criterion. Due to the small BP eleva-
tion level at baseline, however, the margin for BP lowering 
itself was expected to be limited. Nevertheless, BP-decreas-
ing effects were observed for systolic, diastolic and night-
time BP to differing extents. During the first 3 months, the 
systolic BP decreased significantly in both groups, but in 
the placebo group the decrease stagnated between visits 2 
and 3 while in the active group systolic values continued to 
decrease, thus substantiating the efficacy of the nutritional 
intervention. The decrease in diastolic BP was more pro-
nounced in the intervention group during the blind phase, 
but the inter-group difference did not reach statistical sig-
nificance. Subgroup analysis revealed that the antihyper-
tensive effect of the intervention was particularly evident 
in men where a decrease in diastolic BP was seen with a 
significant difference between the groups (p = 0.0387).
Fig. 6  Synergistic effects of 
l-arginine and B vitamins
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The BP-lowering potential of the test product was also 
reflected in the night-time BP reduction (i.e. nocturnal dip-
ping). Studies have shown that attenuated nocturnal blood 
pressure dipping is a better predictor for cardiovascular 
morbidity and mortality than resting BP measurements (for 
review see [67]). Moreover, attenuated nocturnal dipping is 
associated with elevated levels of molecules related to ED 
and atherosclerosis [68]. The continuous improvement in 
nocturnal BP reduction observed over the entire study dura-
tion should be considered clinically relevant since it was 
associated with positive effects on endothelial function.
A limitation of the study was the single-centre design 
since, compared to multi-centre trials, single-centre tri-
als can show a small increase in effect [69]. In our trial, 
this limitation is predominantly compensated by the fol-
lowing facts: (1) the RHI provided objective results; (2) 
the difference in effect between the active intervention and 
the comparator was pronounced; while in the active group 
ΔΔRHI increased significantly, almost no change could be 
detected in the placebo group; (3) all three main parameters 
(endothelial function, BP and homocysteine levels) have 
displayed positive effects.
An important aspect is that the sample also corresponds 
to the typical field of application of a dietetic preparation. 
This supports the high external validity of the trial because 
its design is representative for routine practice where the 
choice would be to offer a dietary product alone or as a die-
tary add-on to drug treatment.
In an earlier large non-interventional study (n = 477) 
with the test product, the systolic BP decreased by 11.4 
from 147.3 to 135.9 mmHg, and the diastolic BP fell by 6.6 
from 88.45 to 81.9 mmHg [70]. However, in that study the 
treatment duration was up to 27.4 months and patients were 
characterized by a higher mean baseline BP so that the 
scope for decreasing BP was larger. These findings seem 
particularly relevant considering the low BP reductions 
that can be achieved with conventional antihypertensive 
drugs. A significant reduction in systolic BP by more than 
6 mmHg and diastolic BP by more than 1.5 mmHg is con-
sidered to be highly relevant [71]. In a recent review, based 
on more than 600,000 participants even modest changes in 
blood pressure were evaluated as being clinically signifi-
cant. For example, a 5-mmHg reduction in systolic blood 
pressure was associated with a 14% reduction in stroke risk 
and a 9% reduction in coronary heart disease risk [72, 73]. 
Thus, it is justified that the positive effects of the test prepa-
ration on BP in our mildly hypertensive patients are inter-
preted as clinically relevant.
Hyperhomocysteinemia may constitute an independent 
risk factor for the development and progression of cardio-
vascular disease associated with ED. Hyperhomocysteine-
mia and vitamin B supplementation have been discussed 
in the context of the opposing effects of l-arginine and 
ADMA on endothelial function, atherosclerosis and car-
diovascular disease risk factors. Homocysteine has been 
shown to inhibit dimethylarginine dimethylaminohydrolase 
(DDAH) which is responsible for ADMA degradation, e.g. 
by oxidative inactivation of the active-site cysteine resi-
due of DDAH, by forming reactive intermediates and by 
enhancing oxidative stress [47].
Since a lowering effect of vitamin B supplementation on 
homocysteine concentration is the subject of some debate 
[47], a need exists for interventional trials investigating the 
effects of B vitamins alone and combined with l-arginine 
at various dosages. Also, different populations need to be 
studied, as pointed out in a recent review by Lundberg and 
colleagues [74], in order to come to sound conclusions 
about how these agents might be recommended to bring 
about successful effects. The current trial fills this gap since 
results were obtained under randomized, controlled condi-
tions with subjects aged 40–65 years with slightly to mod-
erately elevated BP. After 6 months of supplementation, 
homocysteine was significantly decreased from 10.2 to 
8.5 µmol/l in the active group, whereas the values remained 
stable in the placebo group. The difference between the 
groups was statistically significant.
The extent to which the reduction in homocysteine con-
tributed to the improvement in impaired endothelial func-
tion in this trial can, however, not be estimated. Since 
higher homocysteine concentrations are associated with 
enhanced ADMA and superoxide anion radical levels [52], 
a maximal lowering of blood homocysteine levels would 
seem to be a rational goal. The marked reduction in homo-
cysteine levels seen in this trial can be attributed to the syn-
ergistically acting B vitamins, and particularly to folic acid.
Dietary management with l-arginine in combination 
with B vitamins resulted in a significant improvement in 
endothelial function, which may also be mediated by the 
endothelial cell glycocalyx, a novel important structure in 
the function and regulation of the endothelium. It has been 
shown by several authors that the glycocalyx is damaged 
and may be partially destroyed by reactive oxygen species 
(ROS) [75–77]. A disturbed balance of the NO/ROS system 
in our patient cohort may have led to a disturbance of the 
glycocalyx resulting in impaired endothelial cell function. 
Conversely, the nutritional intervention with l-arginine may 
have influenced the endothelial cell glycocalyx and resulted 
in a restauration of this important endothelial structure. 
Recently, novel tools to assess the glycocalyx in patients 
have been introduced [78]. Using these novel methods, 
we will investigate the influence of l-arginine on the gly-
cocalyx and test the hypothesis that l-arginine regulates 
and improves the structure and function of the endothelial 
glycocalyx.
Epidemiologic data support the usefulness of dietary 
supplementation with l-arginine and B vitamins. As such, 
 Eur J Nutr
1 3
the intake of nuts and the Mediterranean diet in general are 
rich sources of l-arginine and B vitamins, and all have been 
proved to significantly reduce cardiovascular morbidity and 
mortality [79–82].
The findings of the current clinical trial confirm the 
excellent safety profile found in an earlier prospective, 
multi-centre, non-interventional dietetic study which was 
also performed with the preparation tested here (n = 484).
The dietetic intervention was proved to be effective, well 
tolerated and safe. The result was achieved through a daily 
supplementation of 2.4 g l-arginine in combination with B 
vitamins, confirming the practical relevance of the synergism 
between these nutrients when used in small amounts. The 
dietary intervention can be considered a physiological alter-
native and addition to conventional treatment of cardiovas-
cular disorders which addresses the underlying pathophysi-
ology. As such, and particularly for subjects with mildly to 
moderately enhanced BP and/or early stages of atherosclero-
sis where impaired endothelial function is evident, the inno-
vative nutritional combination of l-arginine and B vitamins 
might successfully be used to complement the existing thera-
peutic repertoire of methods so that cardiovascular health 
can be maintained, improved or even restored.
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